Garcinia Indica Phytocompounds Show Promise in Fighting Breast Cancer

Strategic Insights -

A recent in silico study from Era's Lucknow Medical College and Hospital in Uttar Pradesh, India, has revealed the potential of Garcinia indica phytocompounds in combating breast cancer. The research demonstrated that three phytocomponents, garcinol, anthocyanin, and hydroxycitric acid, exhibited strong binding affinity for breast cancer-related protein targets, outperforming reference drugs doxorubicin and tetracycline.

Key Takeaways:

  • The study employed in silico methods to evaluate the antibreast cancer potential of three phytocomponents from Garcinia indica.
  • Garcinol, anthocyanin, and hydroxycitric acid demonstrated significant binding affinity for BRCA2, BAX, and BRCA1 protein targets, respectively.
  • Molecular dynamics simulation of the garcinol-BRCA2 complex showed conformational stability throughout the 100 ns simulation period.
  • ADMET and toxicity analyses confirmed favorable drug likeness and non-toxic profiles for the three phytocomponents.
  • PASS prediction, BOILED-Egg, and bioavailability radar assessments further supported their potential as orally bioavailable, CNS-accessible therapeutic candidates.

Statistics:

  • The study involved the evaluation of nine breast cancer-related protein targets.
  • The three phytocomponents demonstrated binding energies (BE) of -7.1 kcal/mol for garcinol, -7.54 kcal/mol for anthocyanin, and -8.28 kcal/mol for hydroxycitric acid, respectively.
  • The dissociation constants (Kd) for the phytocomponents were 6.27 μM for garcinol, 2.96 μM for anthocyanin, and 848.46 nM for hydroxycitric acid.

Sources:

  • Fernando, S., et al. "In Silico Screening, Admet Analysis and Computational Simulation Studies On garcinia Indica Choisy Phytoconstituents As Prospective Antibreast Cancer Agents: A Critical Appraisal of the Neglected Plant." 3 Biotech, vol. 15, no. 7, 2025, pp. 1-14.
  • Era's Lucknow Medical College and Hospital.
  • Springer Heidelberg. (www.springer.com; 3 Biotech - www.springerlink.com/content/2190-572x/)